Trial ID or NCT#





The purpose of this study is to test the safety and efficacy of RO6958688 in combination with atezolizumab in treating patients with advanced solid tumors. In Part I (Dose escalation/schedule finding), the study will test increasing doses of RO6958688 administered either weekly or once every three weeks with a fixed dose of atezolizumab administered once every three weeks. In Part II (Dose expansion), the study will look at safety and efficacy of RO6958688 in combination with atezolizumab at the determined dose and schedule in subjects with different levels of CEA-expression in their solid tumors.

Official Title

An Open-Label, Multicenter, Dose Escalation and Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Tyler Johnson
Gastrointestinal specialist, Medical oncologist
Clinical Assistant Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.


Ben Priestley
(650) 723-2990